In previous in vivo experiments, a clinically achievable DAC dosing strategy followed by NY-ESO-1 TCR-T adoptive transfer resulted in effective T-cell infiltration, tumor clearance, and extension of survival (14). The gene discussed is CTAG1A; the disease is neoplasm.